Odds of new-onset symptoms are significantly lower with GLP-1-RA treatment at 6 months for headache (OR 0.660), visual deficits (OR 0.423), cognitive deficits (OR 0.368), and acetazolamide use (OR 0.295)
However, further research is warranted to develop comprehensive, evidence-based guidelines that fully harness this synergy, maximising therapeutic benefits while minimising associated risks
For most people, this elevation is imperceptible in daily life
Your physician at Jan Medical Group will advise on current availability during your consultation
Indian J Med Res 141(5):516520 Elella SA, Tawfik M, Barseem N, Moustafa W (2017) Prevalence of glucose-6-phosphate dehydrogenase deficiency in neonates in Egypt